(Q38353123)

2 September 2017

1 reference

title

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells (English)

1 reference

2 September 2017

1

B L Levine

1 reference

2 September 2017

publication date

13 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

22

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

79-84

1 reference

Adoptive immunotherapy for cancer or viruses

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

T-cell-based therapies for malignancy and infection in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Targeting T cell costimulation in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Apheresis techniques and cellular immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Moderate and severe adverse events associated with apheresis donations: incidences and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Anticoagulation techniques in apheresis: from heparin to citrate and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Principles of adoptive T cell cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Lentiviral vectors: basic to translational

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

State-of-the-art gene-based therapies: the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Silencing and variegation of gammaretrovirus and lentivirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

The inside out of lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

21 January 2018

Bioreactors get personal

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Treatment of advanced leukemia in mice with mRNA engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Perspective: assembly line immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.5

Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program

21 January 2018

1 reference

12 December 2020

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product

1 reference

12 December 2020

T lymphocyte engineering ex vivo for cancer and infectious disease

1 reference

12 December 2020

Viral vectors: a look back and ahead on gene transfer technology

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

12 December 2020

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

12 December 2020

Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

1 reference

12 December 2020

Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors

1 reference

12 December 2020

Stem cell mobilization.

1 reference

12 December 2020

Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood

1 reference

12 December 2020

Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells

1 reference

12 December 2020

Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1038/CGT.2015.5

1 reference

Dimensions Publication ID

2 September 2017

1039585607

0 references

1 reference